| Budget Amount *help |
¥5,460,000 (Direct Cost: ¥4,200,000、Indirect Cost: ¥1,260,000)
Fiscal Year 2013: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2012: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Fiscal Year 2011: ¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
|
|---|
| Research Abstract |
It has been reported that advanced glycation end products (AGEs) and high mobility group box-1 (HMGB-1), which function as a receptor for AGE (RAGE) ligand, contribute to the pathogenesis of chronic inflammatory diseases, such as atherosclerosis and diabetes. In the present research, we examined the effects of RAGE ligand on the mechanism of rejection and ischemia/reperfusion injury (I/R injury) in organ transplantation. As a result, the antibody therapy for RAGE ligand can contribute to management of the rejection and improvement of I/R injury in organ transplantation.
|
